What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?

We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s (ADMA) portfolio of marketed products and other pipeline updates when it reports second-quarter 2024 results.Let’s see how things have shaped up for the quarter to be reported.Factors to NoteADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company’s top line currently comprises sales of three FDA-approved products, namely – Bivigam (to ...